ArticleLaryngoscope investigative otolaryngology2025
Treatment Durability of Injection Augmentation of Vocal Fold Atrophy.
Article in Laryngoscope investigative otolaryngology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Stem Cell-Based Regeneration of Atrophied Vocal Folds after Recurrent Laryngeal Nerve Injury.International journal of stem cells · 2026Article
- Treatment Durability of Injection Augmentation of Vocal Fold Atrophy.Laryngoscope investigative otolaryngology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Objective: Injection augmentation (or injection laryngoplasty) is a common treatment for presbyphonia. As current injection materials are temporary, it is anticipated that patients injected for presbyphonia will either need a repeat injection or framework surgery to maintain glottal competence (or sufficient glottal closure). Despite the expected temporary nature of these injections, patients report variable durability of effect, and some do not require a repeat injection. The primary aim of this investigation was to identify factors that affect treatment durability of injection augmentation among patients with presbyphonia. Methods: Patients who underwent one or multiple injection augmentations for presbyphonia between May 2008 and September 2017 were extracted from the UW Madison Voice and Swallow Outcomes Database. Variables collected included demographics (age, sex), injection material, volume, duration between injections, date of first and last follow-up, voice therapy (yes/no, number of sessions), and pre- and post-injection voice measures (Maximum Phonation Time, Dysphonia Severity Index, Glottal Function Index score, Vocal Handicap Index Score) in an observational cohort design. For patients receiving one injection (TF group), duration between injection and last follow-up was taken as a durability measure termed "time to follow up." For patients receiving multiple injections (TR group), duration between injection treatments were termed "time to reinjection." Patients receiving one or more injections were compared separately and together (where treatment durability Results: Thirty-five patients with presbyphonia met inclusion criteria (mean age 74.3 years [SD 7.6], 78% male). Twenty patients received only one injection. Repeat injection augmentation was performed in 40% of patients ( Conclusion: Factors that affected treatment durability TF Level of Evidence: III, Retrospective cohort study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.